The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.

A clinical trial for patients with high-grade neuroendocrine tumors is now open for enrollment at Sylvester Comprehensive ...

Current markers include plasma levels of chromogranin A, tumor metastases and Ki67 staining to determine the tumor proliferation rate ... to predict survival in patients with neuroendocrine ...

The approval was based on progression-free survival (PFS) and overall response rates (ORRs ... of Dana-Farber Cancer Institute, Boston, stated in a press release from Exelixis.

After canceling a planned advisory committee meeting, the FDA has approved Exelixis’ Cabometyx for neuroendocrine ... paired triplet misses survival mark in kidney cancer, Exelixis shifts ...

Cabozantinib significantly delayed disease progression in advanced pancreatic and extra-pancreatic neuroendocrine tumors ... With strong progression-free survival benefits demonstrated in the ...

– FDA approval based on the phase 3 CABINET pivotal trial, which demonstrated a statistically significant and clinically meaningful improvement in progression-free survival versus placebo ...

Final progression-free survival results were ... the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for Neuroendocrine and Adrenal Tumors were updated to include ...